AbbVie stock (NYSE: ABBV) experienced a 5% decline yesterday, and the reason is evident: the U.S. FDA has just approved Johnson & Johnson’s Icotyde, the first oral IL-23 inhibitor on the market. This ...

Protagonist Therapeutics (PTGX) shares ended the last trading session 4.7% higher at $101.68. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced that it has regained compliance with ...

This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.

Shares of AbbVie ABBV fell 5.2% on Wednesday, wiping out more than $20 billion in market value. This selloff comes as ...

Bristol Myers BMY recently secured a meaningful label expansion for Sotyktu, with the FDA approving the drug for adults with ...

Only the best dividend stocks can achieve "king" status.

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact ...

Based on current projections, Incannex believes the proceeds from the offering will be sufficient to complete the DReAMzz Phase 2 study for IHL-42X. The Company’s current cash on hand, prior to ...

Diamond Hill Capital, an investment management company, released its “Mid Strategy” fourth-quarter 2025 investor letter. A ...

The number doctors use to demarcate hypertension keeps going down, a trend applauded by many experts, who point to studies ...

The Protecting Patient Access to Cancer and Complex Therapies Act — PACTA — is critical to NJ patients who need access to infusion therapies.